

Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System

January 08, 2018

Next-Generation Ophthalmic Surgical Platform Now Available Across Greater Europe

LAVAL, Quebec, Jan. 8, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), today announced that it has received CE Mark from the European Commission for the Stellaris Elite™ Vision Enhancement System, the company's next generation ophthalmic surgical platform, which includes Vitesse™, the first and only hypersonic, open-port vitrectomy system.

The Stellaris Elite platform is now available throughout greater Europe, including the 28 countries of the European Union, Iceland, Liechtenstein, Norway and Switzerland.

"We're pleased to bring the Stellaris Elite Vision Enhancement System, including the cutting-edge Vitesse technology, to the greater European market," said Joseph C. Papa, chairman and CEO, Valeant. "Because this surgical platform offers the opportunity to continuously add innovative upgrades and enhancements, it enables surgeons to customize their systems and expand their capabilities as their needs evolve without having to invest in a new surgical system."

Already available in the United States, the Stellaris Elite Vision Enhancement System is the first phacoemulsification platform to offer Adaptive Fluidics™, which combines precise aspiration control with predictive infusion management to create a highly responsive and controlled surgical environment for efficient lens removal.* As part of the platform's vitreoretinal capabilities, the Vitesse hypersonic vitrectomy system uses a novel, single-needle design and continuously open-port system that represents the first major advancement in vitreous removal in 40 years. Vitesse will be available exclusively on the Stellaris Elite platform.

About Bausch + Lomb

Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

Forward-looking Statements

This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

**Data obtained in bench study*

Investor Contact:

Arthur Shannon

arthur.shannon@valeant.com

(514) 856-3855

(877) 281-6642 (toll free)

Media Contact:

Lainie Keller

lainie.keller@valeant.com

(908) 927-0617



View original content with multimedia:

<http://www.prnewswire.com/news-releases/bausch--lomb-receives-ce-mark-from-the-european-commission-for-the-stellaris-elite-vision-enhancement-system-including-the-vitesse-vitrectomy-system-300578252.html>

SOURCE Valeant Pharmaceuticals International, Inc.

Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)



LEGAL NOTICE

PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

©2025 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**

